Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today the European Medicines Agency (EMA) has appointed a rapporteur and a co-rapporteur as part of the pre-submission process related to Humanigen’s plan to submit an MAA for the use of lenzilumab to treat patients hospitalized with COVID-19. These appointments by the Committee for Medicinal Products for Human Use (CHMP) are an important step in the pre-submission process leading up to the submission of the MAA. Humanigen plans to request accelerated assessment of the MAA as part of the pre-submission process.

“Highlighting the ongoing need globally for therapeutics to treat patients hospitalized with COVID-19, in the EU in the most recent week for which data is available, there were 7,664 new hospitalizations and 4,429 deaths reported for COVID-19,” said Cameron, Durrant, MD, Chief Executive Officer, Humanigen.¹ “We remain committed to bringing lenzilumab to hospitalized patients with COVID-19 and as part of this effort, we plan to submit our MAA to the EMA as soon as possible.”

EU legislation allows for accelerated assessment of an MAA, reducing review time from 210 days to 150 days not counting clock stops for applicants to provide additional information, if CHMP determines a product is a major public health interest; however, this decision has no impact on the eventual CHMP opinion on whether a marketing authorization should be granted.

About Humanigen

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen has submitted lenzilumab to Medicines and Health Regulatory Agency in the United Kingdom for a rolling review towards potential Marketing Authorization. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.